New tuberculosis therapeutics: a growing pipeline.

Novel chemotherapeutic drugs are needed to improve tuberculosis (TB) control, especially in the developing world. Given the magnitude of the problem and the resources available in countries that have the highest burden of disease, the present standards of care for the treatment of drug-susceptible TB, drug-resistant TB, TB/human immunodeficiency virus (HIV) coinfection, and latent TB infection are all unsatisfactory. Because no truly novel compounds for the treatment of TB have been discovered in the past 40 years, the recent enhanced activity in the research and development of new TB drugs is extremely encouraging. Seven compounds are presently in clinical development specifically for the treatment of TB. Other known antibiotic compound families are being investigated preclinically, in an attempt to identify new antimicrobial drugs with specific antituberculous activity. In addition, novel targets have been identified and are the subject of efforts to validate their potential usefulness in the treatment of TB.

[1]  R. Chaisson,et al.  Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial , 2002, The Lancet.

[2]  S. Gillespie,et al.  The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[3]  D. Mitchison.  Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. , 1996, Society for Applied Bacteriology symposium series.

[4]  D. Bonner,et al.  In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. , 2000, The Journal of antimicrobial chemotherapy.

[5]  R. Chaisson,et al.  Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis , 2002, Antimicrobial Agents and Chemotherapy.

[6]  Rossella Fioravanti,et al.  Bactericidal Activities of the Pyrrole Derivative BM212 against Multidrug-Resistant and Intramacrophagic Mycobacterium tuberculosis Strains , 1998, Antimicrobial Agents and Chemotherapy.

[7]  D. Mitchison,et al.  Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[8]  M. Cynamon,et al.  In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis , 2002, Antimicrobial Agents and Chemotherapy.

[9]  W. Bishai,et al.  Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[10]  J. Norton,et al.  Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis , 2002 .

[12]  H. Lode,et al.  Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study , 2004, Antimicrobial Agents and Chemotherapy.

[13]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[14]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[15]  D. Mitchison,et al.  The search for new sterilizing anti-tuberculosis drugs. , 2004, Frontiers in bioscience : a journal and virtual library.

[16]  R. Chaisson,et al.  Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[17]  Marianne Terrot,et al.  Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. , 2003, Journal of combinatorial chemistry.

[18]  P. Chapman.  Ingrowing Toe-nail , 1934 .

[19]  C. Grassi.  New drugs for tuberculosis. , 1997, Expert opinion on investigational drugs.

[20]  D. Mitchison.  Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. , 1993, The American review of respiratory disease.

[21]  R. Chaisson,et al.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[22]  N. Lounis,et al.  Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice , 2001, Antimicrobial Agents and Chemotherapy.

[23]  L. Jia,et al.  Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug , 2005, British journal of pharmacology.

[24]  TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation. , 1950, British medical journal.

[25]  E. Hershfield,et al.  Tuberculosis: a comprehensive international approach , 1993 .

[26]  S. J. Shane.  New drugs for tuberculosis. , 1959, Canadian Medical Association journal.

[27]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[28]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.